Clinical Trial Update: Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

View source ↗

Summary

A completed real-world study assessing the effectiveness and tolerability of alpelisib in patients with PIK3CA-mutant breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Piqray (alpelisib) (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: COMPLETED